Navigation Links
A Drug With Efficacy Superior to That of Xenical at Inducing Weight Loss Would Earn a 40 Percent Patient Share in the Obesity Drug Market
Date:6/12/2008

Advantages in Efficacy and Delivery Will Make Qnexa the New Clinical Gold Standard Drug by 2011, According to a New Report from Decision Resources

WALTHAM, Mass., June 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug that is more effective than Roche's Xenical at inducing weight loss would earn a 40 percent patient share in the obesity drug market, according to surveyed primary care physicians. Although other efficacy measures-such as the effect on weight maintenance-are also important to prescribers, the biggest unmet need within this indication is a therapy that can consistently induce more than ten percent weight loss. The Food and Drug Administration currently requires that a drug elicit between five and ten percent weight loss to get approval.

The new report entitled Obesity: Current Pipeline Falls Short of Physicians' Expectations for Efficacy and Safety finds that Vivus's Qnexa will become Decision Resources' proprietary clinical gold standard by 2011 due to its competitive advantages in efficacy and delivery over the 2006 gold standard, Xenical. By 2016 however, Orexigen's Empatic will supersede Qnexa due to its advantage in safety. Both Empatic and Qnexa are fixed dose combinations of currently marketed central nervous system agents used for indications like epilepsy, alcohol dependence and depression.

"Phase II clinical trial data revealed that Qnexa caused a greater overall weight reduction compared with pooled data for Xenical after a 24-week treatment period," said Donny Wong, Ph.D., principal analyst at Decision Resources. "According to physicians we surveyed, Empatic's overall score for safety and tolerability is better, based on the perception that this combination agent is more conducive to longer-term treatment."

About the Report

Obesity: Current Pipeline Falls Short of Physicians' Expectations fo
'/>"/>

SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
5. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
6. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)...REXEL International Corporation (Nasdaq: PRXL ),...der, today announced that it has opened an office ... clinical research capabilities. With the addition...oughout five important biopharmaceutical centers i...zil, Chile, and Mexico. This expansion further str...
(Date:11/19/2008)... Science Corporation,researcher, Dan Tinker, pres...nual Conference in Washington, DC this week indica...mers. The computerized brain plasticity-based,Br...hat target auditory and,language systems. The ex...ments in cognition by improving speed and accuracy...
(Date:11/19/2008)...l significance , , ISELIN, N.J., Nov. 19 /...aq: PARS ) today announced results from its Phas...E) drug delivery technology formulated with 3% Dic...r, randomized, double-blinded, placebo-controlled ...pany,s 3% Diclofenac Diethanolamine NanoEmulsion c...
(Date:11/19/2008)...Biotech scientists increasingly are applying genom...understand the effects of novel drug candidates on...neering & Biotechnology News ( GEN ). They ar...ound,s mechanism of action and eventually developi... the November 15 issue of GEN . ( http://www.gene...
Breaking Medicine Technology:PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2GEN Reports on the Trend Toward Predictive Toxicogenomics 2Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 4097 1Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 4097 2Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 4097 3Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 4097 4IPC The Hospitalist Company Announces Board of Director Member Changes 14788 1IPC The Hospitalist Company Announces Board of Director Member Changes 14788 2IPC The Hospitalist Company Announces Board of Director Member Changes 14788 3IPC The Hospitalist Company Announces Board of Director Member Changes 14788 4IPC The Hospitalist Company Announces Board of Director Member Changes 14788 5IPC The Hospitalist Company Announces Board of Director Member Changes 14788 6IPC The Hospitalist Company Announces Board of Director Member Changes 14788 7IPC The Hospitalist Company Announces Board of Director Member Changes 14788 8IPC The Hospitalist Company Announces Board of Director Member Changes 14788 9IPC The Hospitalist Company Announces Board of Director Member Changes 14788 10IPC The Hospitalist Company Announces Board of Director Member Changes 14788 11IPC The Hospitalist Company Announces Board of Director Member Changes 14788 12IPC The Hospitalist Company Announces Board of Director Member Changes 14788 13IPC The Hospitalist Company Announces Board of Director Member Changes 14788 14Featured Stocks on Todays Edition of WallSt nets 3 Minute Press Show 3A INIX BPAX GLOW LB 14786 1Featured Stocks on Todays Edition of WallSt nets 3 Minute Press Show 3A INIX BPAX GLOW LB 14786 2Featured Stocks on Todays Edition of WallSt nets 3 Minute Press Show 3A INIX BPAX GLOW LB 14786 3Featured Stocks on Todays Edition of WallSt nets 3 Minute Press Show 3A INIX BPAX GLOW LB 14786 4MedCom Announces Court Rules Card Activation Technologies Patent Is Valid 14785 1MedCom Announces Court Rules Card Activation Technologies Patent Is Valid 14785 2MedCom Announces Court Rules Card Activation Technologies Patent Is Valid 14785 3
... WIRE)--Apr 16, 2007 - Novelos,Therapeutics, Inc. ... on the development of therapeutics to treat cance... in collaboration with,Dr. Kenneth Tew and Dr. Dan...Carolina (MUSC), is making two poster presentation...esearch annual meeting.,These presentations will h...
...IRE)--Apr 16, 2007 - ZIOPHARM Oncology,Inc. (NASD...indibulin (ZIO-301) at the American Association of...ese data demonstrate that,indibulin has distinct b...n binding agents and strongly suggest a very diffe... peripheral,neuropathy. While indibulin binds to t...
Other Medicine Technology:Novelos Therapeutics and MUSC Present Two Posters at AACR 2007,Annual Meeting 2ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR 2ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR 3
(Date:11/21/2008)...d schools need to work together to stop abusive be...(HealthDay News) -- Behavior that was once dismiss...ing. , And as mounting research shows the negat...al-health professionals, schools, parents and even...mbat this threatening behavior. , "Bullying sh...
(Date:11/21/2008)... Nov. 21 During a memo...ard G. Rendell today remembered Lieutenant Governo...important partner in public service, and a tireles..., "As the first woman elected lieutenant governo...t," said Governor Rendell. "Her family and her fai...
(Date:11/21/2008)...remain cautious about future antibiotic resistance...21 (HealthDay News) -- People with moderate to sev...ay be able to reduce the frequency of exacerbation...ic, a new report says. , The study, published ...ournal of Respiratory and Critical Care Medicine ,...
(Date:11/21/2008)...., Nov. 21 New research...r a smokeless, spitless tobacco product aimed at y...ve found that RJ Reynolds, Camel Snus - touted as ...ontains surprisingly high levels of nicotine. , ...t other snuff products," said Bruce Adkins of the ...
Breaking Medicine News(10 mins):Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 2Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 3Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3
...calcium to the diet may help reduce the risk of de...udy of more than 95,000 women who never had kidney...tones over the eight years of the study. Women who...ent lower risk of developing kidney stones compare...
...ary disease that affects thousands of Americans, a...rding to a new study.// Researchers identified nea... schizophrenia. The known risk factors such as soc...amily history of schizophrenia, as well as unteste...
...e higher in colder months. So if you’re worried ab...go get them checked now rather than wait till the ...a study involving about 500 otherwise healthy men ...ir cholesterol checked on a quarterly basis over t...
...ive joint disease that affects more than 21 millio...symptoms are pain, stiffness, reduced joint range ...h as getting up from a chair, walking, balance and...s. Pain-reducing medications such as acetaminophen...
Other Medicine News:
...ormance Tecoflex stents that save inventory, shelf...eteral Stents accommodate ureteral lengths from 22...ws the Quadra-Coil to glide over any guidewire and...provide ease of placement and patient comfort in a...
...temporary internal drainage from the ureteropelvic...is engineered for ease of placement and patient co... designed for repositioning and ease of removal. A... that when activated, attracts and holds water and...
The CMV IgM enzyme immunoassay is for the qualitative detection of antibodies to cytomegalovirus. The CMV IgM assay is primarily indicated for the detection of early or recent infection.
The Shandon Sequenza uses the Shandon Coverplate system which ensures consistency and excellent staining quality. , , ,Allows the user to perform large immunostaining runs (up to 50 slides/run
Medicine Products: